QUALITY OF RECOVERY AFTER INTRAOPERATIVE MORPHINE OR METHADONE IN PATIENTS UNDERGOING LAPAROSCOPIC CHOLECYSTECTOMY

We hypothesized that methadone treatment would beneficially affect patient-perceived quality of recovery after laparoscopic cholecystectomy under total intravenous anesthesia. The primary outcome was assessed using the Quality of Recovery Questionnaire (QoR-40), a 40-item quality of recovery scoring system, on postoperative day (POD) 1. In addition, the effects of both opioids on early clinical recovery variables, such as the time to eye opening, the occurrence of nausea and vomiting, pain score, use of analgesics, and length of PACU stay, were determined.

Methods. This randomised trial was approved by the Research Ethics Committee of the School of Medical and Health Sciences, Pontifical Catholic University of São Paulo.

Study sequence No premedication will be applied to the patients. Patients´ preoperative data including age, gender, physical status and, BMI will be collected. Subjects will be randomized using a computer-generated (www.random.org) table of random numbers into 2 groups: MT (methadone 0.1 mg.kg-1) or MF (morphine 0.1 mg.kg-1). Group assignments were sealed in sequentially numbered opaque envelopes that were opened after patient inclusion in the study. All care providers, researchers, and patients were blinded to group assignments. Two study 10-mL syringes will be prepared by an anesthesiologist independent of the study. Syringe 1 to be used during intraoperative phase and syringe 2 as a rescue for postoperative pain. Methadone 0.1 mg.kg-1 (made up to 10 mL with normal saline) or morphine 0.1 mg.kg-1 (made up to 10 mL with normal saline) will be drawn into each syringe which will be offered to the anesthesia provider after the opaque envelope is opened.

Anesthetic and Surgical Management After arrival in the operating room, standard ASA monitors will be applied. Lidocaine (30 mg) will be administered intravenously immediately after venoclysis. After anesthesia induction, capnographic monitoring will be added. Anesthesia will be induced with remifentanil 0.5 µg.kg-1.min-1 over three minutes followed by propofol 2.0 mg. kg-1. Rocuronium 0.6 mg.kg-1 will be administered to facilitate tracheal intubation. Anesthetic maintenance will be achieved with a continuous infusion of remifentanil 0.3 µg.kg-1.min-1 and propofol 4 to 6 mg. kg-1. h-1. Ventilation will be controlled mechanically to maintain an end-tidal carbon dioxide concentration of 30-40 mmHg using a 50% oxygen-air gas mixture. Immediately after the induction of anesthesia, patients will receive intravenously: MT group - Methadone 0.1 mg/kg or MF group - morphine 0.1 mg/kg. Patients who exhibit reductions in systolic arterial pressure (SAP) greater than 30% or heart rate (HR) reductions to less than 50 bpm will be given ephedrine (10 mg) and atropine (0.5 mg), respectively. Normal saline will be used for fluid replacement therapy at a rate of 500 ml throughout the first 30 minutes, and, then, 2 ml/kg/h until the end of the surgical procedure. All of the participants will receive dexamethasone (8 mg) and ketoprofen (100 mg) at the onset of surgery and ondansetron (4 mg) and dipyrone (1 g). Residual neuromuscular blockade will be antagonized by atropine (0.01 mg/ kg) and neostigmine (0.015 mg/kg). Extubation will be performed after awakening. The time elapsed from discontinuation of the anesthetics until the eye opening will be registered.

When stable vital signs and respiration are confirmed, all patients will be transferred to the post-anesthesia care unit (PACU). Early recovery times includes time to eye opening (time from the discontinuation of anaesthetics to eye opening) and time to Aldrete score ≥ 9. Data related to the occurrence of pain, nausea and vomiting at the PACU will be recorded. Pain will be assessed while at rest and after asking the subjects to cough, every 15 minutes using a 0-10 numeric pain rating scale (NRS), where zero meant no pain and 10 the worst imaginable pain. When stable vital signs and respiration are confirmed, all patients will be transferred to the post-anesthesia care unit (PACU). Early recovery times includes time to eye opening (time from the discontinuation of anaesthetics to eye opening) and time to Aldrete score ≥ 9. Data related to the occurrence of pain, nausea and vomiting at the PACU will be recorded. Pain will be assessed while at rest and after asking the subjects to cough, every 15 minutes using a 0-10 numeric pain rating scale (NRS), where zero meant no pain and 10 the worst imaginable pain. One or two mL from the solution previously prepared (Syringe 2) will be administered intravenously every 15 minutes to maintain the pain score below 3 (1 mg when the pain score is <7 and 2 mg when it is ≥7). Following discharge from the PACU (minimum stay 60 minutes and Aldrete score ≥ 9), all of the participants will receive ketoprofen (100 mg) every 12 hours and dipyrone (30 mg.kg-1, maximum 1 g) every six hours intravenously. Whenever patients judge that their analgesia is insufficient, tramadol (100 mg) will be administered intravenously at eight-hour minimum intervals. Postoperative nausea and vomiting (PONV) will be treated with ondansetron (4 mg) intravenously. An investigator who will be blinded to group assignment will collect all postoperative outcome data 24 hours after surgical procedure. Subjects will rate the higher score of pain (NRS) during the hospital ward stay. Tramadol consumption and the number of nausea and vomiting episodes will also be recorded. These findings will be confirmed with the ward nursing staff. All subjects will stay at hospital for at least 24 hours.